Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage Today“Striking” Colon Cancer Data Spur Mid-Presentation Ovation at ESMO

With two cycles of neoadjuvant immunotherapy, nearly every patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response. At a median follow-up of 13.1 months, the disease-free survival (DFS) rate was 100% vs. an expected rate for this patient population of 15%.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form